source
- Neurocrine’s rare-disease drug approved but later linked to deaths and serious side effectsNeurocrine Biosciences received regulatory approval for a rare‑disease therapy after a small clinical trial showed modest efficacy and side effects that were considered manageable. The decision was…
- Opinion: How to disrupt the health misinformation business modelOne way to fight medical misinformation: make it easier for people to understand when they are being manipulated, write Paul Martin Jensen and Avi Tuschman.STAT · 3h ago↗ source